{"id":"45a51a2a88c5","type":"article","url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","title":"GDMT na functioneel complete revascularisatie: prognostische impact","title_en":"Prognostic impact of guideline-directed medical therapy after functionally complete revascularisation in patients with obstructive coronary artery diseases.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-325670","source_url":"https://doi.org/10.1136/heartjnl-2025-325670","authors":["Yingyang Geng","Changdong Guan","Yao Jiang","WeiXian Yang","Bo Yu","Guosheng Fu","Jun Pu","Xinkai Qu","Qi Zhang","Yanyan Zhao","Lilei Yu","Yunfei Huang","Shengxian Tu","Shubin Qiao","Lei Song"],"significance":6,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/","https://hartvaat.nl/kennis/cardiometabool/gewichtsreductie-leefstijl-hart/"],"congress":"","summary_en":"This analysis showed that optimal guideline-directed medical therapy further improves prognosis after functionally complete revascularization, demonstrating that PCI and pharmacotherapy provide complementary rather than competing benefit.","created":"2026-07-03T10:32:11Z","updated":"2026-07-03T13:31:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse toonde dat optimale GDMT na functioneel complete revascularisatie de prognose verder verbetert. Revascularisatie vervangt medicamenteuze therapie niet.","abstract_original":"OBJECTIVE: Functional complete revascularisation (FCR) has been proven to be associated with superior prognosis following percutaneous coronary intervention. Whether guideline-directed medical therapy (GDMT) still impacts clinical outcomes in patients who have achieved FCR requires further evaluation. METHODS: The study population was drawn from patients who achieved FCR in the FAVOR III China trial, defined as a quantitative flow ratio (QFR)-based residual functional Synergy between percutaneous coronary intervention with taxus and cardiac Surgery score of 0, measured only in vessels with QFR≤0.80. GDMT was defined as the combination of single or dual antiplatelet therapy, a beta-blocker and a statin, with or without an ACE inhibitor or angiotensin receptor blocker, according to contemporary guideline recommendations. Patients were categorised into the GDMT group (compliance with all 4 agents) or non-GDMT group (compliance with 0-3 agents). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE) at 3 years, a composite of death, myocardial infarction, stroke and ischaemia-driven revascularisation. RESULTS: Among 3221 (85.2%) patients who achieved FCR, a total of 1964 (61.2%), 1919 (59.9%), 1545 (48.4%), 1483 (46.6%) and 1084 (35.3%) patients adhered to GDMT at 1 month, 6 months, 1 year, 2 years and 3 years, respectively. The MACCE occurred in 313 (10.2%) patients through 3 years. The rate of MACCE was similar between GDMT and non-GDMT groups within the first year, but significantly lower in the GDMT group from the second year (adjusted HR: 0.66, 95% CI: 0.51 to 0.85; p<0.01) and sustained until the third year (adjusted HR: 0.65, 95% CI: 0.50 to 0.85; p<0.01), compared with the non-GDMT group. CONCLUSIONS: In patients who achieved FCR, the benefit of good adherence to GDMT remained significant, starting from the second year and continuing up to 3 years. TRIAL REGISTRATION NUMBER: NCT03656848."}